Teladoc Health (NYSE:TDOC) Reaches New 52-Week Low – Time to Sell?

Teladoc Health, Inc. (NYSE:TDOC)’s share price reached a new 52-week low during mid-day trading on Friday . The stock traded as low as $6.34 and last traded at $6.3250, with a volume of 4744722 shares. The stock had previously closed at $6.53.

Analyst Upgrades and Downgrades

Several brokerages have recently commented on TDOC. Bank of America reduced their target price on shares of Teladoc Health from $9.00 to $8.00 and set a “neutral” rating on the stock in a research note on Tuesday, November 25th. BMO Capital Markets began coverage on shares of Teladoc Health in a research report on Thursday, November 13th. They issued a “market perform” rating and a $8.00 price target on the stock. Evercore ISI dropped their price objective on shares of Teladoc Health from $9.00 to $8.00 and set an “in-line” rating for the company in a report on Thursday, October 30th. Citigroup cut their target price on shares of Teladoc Health from $10.00 to $9.00 and set a “neutral” rating for the company in a research note on Friday, January 9th. Finally, Barclays started coverage on Teladoc Health in a research report on Tuesday, December 9th. They set an “equal weight” rating and a $8.50 price target on the stock. Five equities research analysts have rated the stock with a Buy rating, twelve have issued a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average target price of $9.50.

Teladoc Health Price Performance

The stock’s 50-day moving average price is $7.29 and its 200-day moving average price is $7.77. The company has a market capitalization of $1.11 billion, a price-to-earnings ratio of -4.89 and a beta of 2.04. The company has a quick ratio of 2.60, a current ratio of 2.70 and a debt-to-equity ratio of 0.71.

Teladoc Health (NYSE:TDOC) last issued its quarterly earnings results on Wednesday, October 29th. The health services provider reported ($0.21) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.26) by $0.05. Teladoc Health had a negative net margin of 8.84% and a negative return on equity of 10.59%. The business had revenue of $626.44 million during the quarter, compared to analyst estimates of $625.66 million. During the same quarter last year, the business posted ($0.19) earnings per share. Teladoc Health’s revenue for the quarter was down 2.2% compared to the same quarter last year. Teladoc Health has set its Q4 2025 guidance at -0.250–0.100 EPS. Equities research analysts anticipate that Teladoc Health, Inc. will post -1.16 earnings per share for the current year.

Insider Transactions at Teladoc Health

In related news, insider Adam C. Vandervoort sold 5,720 shares of the firm’s stock in a transaction dated Tuesday, December 2nd. The stock was sold at an average price of $7.49, for a total value of $42,842.80. Following the transaction, the insider owned 80,732 shares in the company, valued at $604,682.68. This trade represents a 6.62% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Charles Divita III sold 17,138 shares of the business’s stock in a transaction dated Thursday, December 11th. The stock was sold at an average price of $7.63, for a total value of $130,762.94. Following the sale, the chief executive officer directly owned 201,036 shares of the company’s stock, valued at $1,533,904.68. This represents a 7.86% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last three months, insiders sold 33,288 shares of company stock worth $251,684. 0.58% of the stock is owned by insiders.

Hedge Funds Weigh In On Teladoc Health

Several large investors have recently bought and sold shares of TDOC. AFG Fiduciary Services Limited Partnership bought a new stake in shares of Teladoc Health during the 4th quarter valued at $92,000. IFP Advisors Inc grew its stake in shares of Teladoc Health by 412.1% during the third quarter. IFP Advisors Inc now owns 3,989 shares of the health services provider’s stock worth $31,000 after purchasing an additional 3,210 shares during the period. CIBC Bancorp USA Inc. bought a new stake in Teladoc Health in the third quarter valued at about $145,000. CANADA LIFE ASSURANCE Co increased its holdings in Teladoc Health by 8.0% in the third quarter. CANADA LIFE ASSURANCE Co now owns 60,231 shares of the health services provider’s stock valued at $494,000 after purchasing an additional 4,458 shares during the last quarter. Finally, Verition Fund Management LLC lifted its stake in Teladoc Health by 152.0% in the third quarter. Verition Fund Management LLC now owns 218,572 shares of the health services provider’s stock valued at $1,690,000 after buying an additional 131,833 shares during the period. 76.82% of the stock is currently owned by institutional investors and hedge funds.

Teladoc Health Company Profile

Teladoc Health, Inc is a leading global provider of virtual healthcare services, offering on-demand medical consultations via phone, video, and mobile app platforms. The company connects patients with licensed physicians and specialists for non-emergency medical issues, mental health support, dermatology, and chronic condition management. By leveraging digital technologies and data analytics, Teladoc aims to enhance accessibility, reduce healthcare costs, and improve patient outcomes through personalized care plans and remote monitoring.

Teladoc’s service portfolio includes general medical visits, behavioral health sessions, expert medical services for complex cases, and wellness programs designed to support chronic disease management such as diabetes, hypertension, and heart disease.